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Abstract:  
Background: The incidence of Escherichia coli bloodstream infections (EC-
BSIs), particularly those caused by antibiotic-resistant strains, is 
increasing in the UK and internationally. This is a major public health 
concern but the evidence base to guide interventions is limited.  
 
Methods: Incidence of EC-BSIs and E. coli urinary tract infections (EC-
UTIs) in one UK region (Oxfordshire) were estimated from anonymised 
linked microbiological and hospital electronic health records, and 
modelled using negative binomial regression based on microbiological, 
clinical and healthcare exposure risk factors. Infection severity, 30-day 
all-cause mortality, and community and hospital co-amoxiclav use were 
also investigated. 
 
Findings: From 1998-2016, 5706 EC-BSIs occurred in 5215 patients, and 
228376 EC-UTIs in 137075 patients. 1365(24%) EC-BSIs were nosocomial 
(onset >48h post-admission), 1863(33%) were community (>365 days post-
discharge), 1346(24%) were quasi-community (31-365 days post-discharge), 
and 1132(20%) were quasi-QRVRFRPLDOGD\VSRVW-discharge). 1413(20%) 
EC-BSIs and 36270(13%) EC-UTIs were co-amoxiclav-resistant (41% and 30%, 
respectively, in 2016). Increases in EC-BSIs were driven by increases in 
community (10%/year (95% CI:7%-13%)) and quasi-community (8%/year (95% 
CI:7%-10%)) cases. Changes in EC-BSI-associated 30-day mortality were at 
most modest (p>0*03), and mortality was substantial (14-25% across 
groups). By contrast, co-amoxiclav-resistant EC-BSIs increased in all 
groups (by 11%-19%/year, significantly faster than susceptible EC-BSIs, 
pheterogeneity<0*001), as did co-amoxiclav-resistant EC-UTIs (by 13%-
29%/year, pheterogeneity<0*001). Co-amoxiclav use in primary-care 
facilities was associated with subsequent co-amoxiclav-resistant EC-UTIs 
(p=0*03) and all EC-UTIs (p=0*002).  
 
Interpretation: Current increases in EC-BSIs in Oxfordshire are primarily 
community-associated, with high rates of co-amoxiclav resistance, 
nevertheless not impacting mortality. Interventions should target 
primary-care facilities with high co-amoxiclav usage. 
 
Funding: National Institute for Health Research. 
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Abstract  
Background: The incidence of Escherichia coli bloodstream infections (EC-BSIs), 
particularly those caused by antibiotic-resistant strains, is increasing in the UK and 
internationally. This is a major public health concern but the evidence base to guide 
interventions is limited.  
Methods: Incidence of EC-BSIs and E. coli urinary tract infections (EC-UTIs) in one UK 
region (Oxfordshire) were estimated from anonymised linked microbiological and hospital 
electronic health records, and modelled using negative binomial regression based on 
microbiological, clinical and healthcare exposure risk factors. Infection severity, 30-day all-
cause mortality, and community and hospital co-amoxiclav use were also investigated. 
Findings: From 1998-2016, 5706 EC-BSIs occurred in 5215 patients, and 228376 EC-UTIs 
in 137075 patients. 1365(24%) EC-BSIs were nosocomial (onset >48h post-admission), 
1863(33%) were community (>365 days post-discharge), 1346(24%) were quasi-community 
(31-365 days post-discharge), and 1132(20%) were quasi-nosocomial (30 days post-
discharge). 1413(20%) EC-BSIs and 36270(13%) EC-UTIs were co-amoxiclav-resistant 
(41% and 30%, respectively, in 2016). Increases in EC-BSIs were driven by increases in 
community (10%/year (95% CI:7%-13%)) and quasi-community (8%/year (95% CI:7%-10%)) 
cases. Changes in EC-BSI-associated 30-day mortality were at most modest (p>0·03), and 
mortality was substantial (14-25% across groups). By contrast, co-amoxiclav-resistant EC-
BSIs increased in all groups (by 11%-19%/year, significantly faster than susceptible EC-
BSIs, pheterogeneity<0·001), as did co-amoxiclav-resistant EC-UTIs (by 13%-29%/year, 
pheterogeneity<0·001). Co-amoxiclav use in primary-care facilities was associated with 
subsequent co-amoxiclav-resistant EC-UTIs (p=0·03) and all EC-UTIs (p=0·002).  
Interpretation: Current increases in EC-BSIs in Oxfordshire are primarily community-
associated, with high rates of co-amoxiclav resistance, nevertheless not impacting mortality. 
Interventions should target primary-care facilities with high co-amoxiclav usage. 
Funding: National Institute for Health Research.  
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Research in context 
Evidence before this study 
We searched PubMed for publications from inception up until 
2FWREHUZLWKWKHWHUPV³Escherichia coli´³E. coli´ ³EDFWHUDHPLD´, ³EORRGVWUHDP
LQIHFWLRQ´restricting the search to English language articles, and also reviewed references 
from retrieved articles. Escherichia coli (E. coli) is the most common cause of bloodstream 
infection, and the incidence of E. coli bloodstream infection, and particularly antibiotic-
resistant infections, is increasing in the UK and internationally. Although the UK government 
aims to reduce healthcare-associated E. coli bloodstream infection, there is only limited 
evidence to inform appropriate interventions. 
 
Added value of this study 
We investigated potential drivers for these increases in incidence by exploiting available 
linked electronic health records over 19 years for ~5200 patients with E. coli bloodstream 
infection and ~140000 with E. coli urinary tract infection, together with community 
antimicrobial prescribing data for the most recent six years. Our study identified several 
findings with significant implications for health policy and patient care: 
x Increases in the incidence of E. coli bloodstream infections were driven mainly by 
non-hospital-associated cases; however, neither patients with previous urinary tract 
infections nor having previously had urine specimens sent from catheters appeared 
to be driving the increases 
x Co-amoxiclav-resistant bloodstream infections rose significantly faster than co-
amoxiclav-susceptible bloodstream infections, with the greatest number of co-
amoxiclav-resistant bloodstream infections in 2016 being in patients discharged more 
than a month previously (i.e. community-associated) 
4 
x Higher co-amoxiclav use in primary care was associated with higher rates of both co-
amoxiclav-resistant E. coli urinary tract infections and E. coli urinary tract infections 
overall, supporting drives to reduce broad-spectrum and inappropriate antibiotic use 
in primary care 
x Despite substantial increases in co-amoxiclav-resistant bloodstream infections there 
was no evidence that mortality was increasing in these cases; this does not support 
moving to broader empiric antibiotic prescribing in hospitals (i.e. carbapenems, 
piperacillin-tazobactam) 
Implications of all available advice 
This suggests that government strategies to effectively reduce E. coli bloodstream infections 
should target community settings, as well as healthcare-associated settings. The absence of 
an increased mortality signal suggests that co-amoxiclav resistant E. coli infections are 
either being successfully treated by dual empiric therapy in severe cases (e.g. with 
concomitant gentamicin), can be ³UHVFXHG´ once isolate susceptibilities become available, or 
currently deployed phenotypic susceptibility testing breakpoints do not adequately correlate 
with clinical outcome.   
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Introduction  
Escherichia coli is a major cause of bloodstream infection (BSI)1 and a critical antimicrobial 
resistance (AMR) concern;2 rates are rising worldwide.3 For example, E. coli bloodstream 
infections (EC-BSIs) reported (voluntarily) to Public Health England rose by 44% between 
2003-2011;4 a similar 68% increase between 1999-2011 was seen in Oxfordshire, UK.5 
Mandatory reporting was introduced in England in July 2011; a further 28% increase in EC-
BSI incidence occurred by July-September 2016, to 78·8 cases/100,000 population.6  
 
In the UK, as elsewhere, most (>70%) EC-BSIs are identified within two days of hospital 
admission.6 However, the impact of previous hospital-exposure on trends in EC-BSI has not 
been comprehensively investigated, with only two relevant previous studies, one in the 
Calgary Health Region 2000-20067, and another in Oxfordshire in 20115 considering only 
whether blood cultures were taken outside or inside hospital. EC-BSI source may also differ 
by hospital-exposure. In a recent study, ~50% of UK EC-BSIs were considered most likely 
due to urinary tract infections (UTIs);8 gastrointestinal foci are however more common in 
inpatients.6 
 
30-day all-cause mortality following EC-BSI is ~16%;9 and could rise given the impact of 
increasing AMR on treatment options.2 In Oxfordshire, EC-BSI incidence rises through 2011 
were essentially confined to ciprofloxacin-, co-amoxiclav-, cefotaxime- and/or 
aminoglycoside-resistant organisms.5 The reasons for rising EC-BSI more generally are 
unclear, with increased antibiotic usage implicated in some, but not all, studies.10±15 In the 
UK and internationally, co-amoxiclav is used as empiric treatment for many infection 
syndromes and for prophylaxis.10,16 Hence, trends in co-amoxiclav resistance are particularly 
important.  
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We therefore aimed to investigate possible drivers of changes in EC-BSI incidence and 
antibiotic susceptibilities in Oxfordshire over the last two decades, while stratifying for 
hospital-exposure. We hypothesized that increases may be due to features of the at-risk 
population (therefore exploring demographics, recurrent infections, increased 
ascertainment), healthcare-history (previous urine cultures, and specifically previous 
catheter specimens, previous admission diagnoses, antibiotic usage), and/or the bacteria 
(exploring mortality/severity, AMR burden). 
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Methods 
The Infections in Oxfordshire Research Database (IORD)17 records all admissions to the 
Oxford University Hospitals National Health Service Foundation Trust (OUH), Oxfordshire, 
UK, from April 1997, linked by patient with microbiology and biochemistry/haematology 
results. The four hospitals within OUH provide all acute care, microbiology and pathology 
services in the region (~680,000 individuals). Out-of-hospital mortality was determined by 
updates from a national information system recording all UK deaths. IORD has generic 
Research Ethics Committee and Health Research Authority approvals (14/SC/1069, ECC5-
017(A)/2009). Data on antibiotic prescribing and numbers of registered patients for each 
general practice were obtained from the Health and Social Care Information Centre 
(available January 2011-December 2016 only). 
 
The primary study outcome was EC-BSI, defined as E. coli isolated from blood cultures 
taken 01/Jan/1998-31/Dec/2016 inclusive, including polymicrobial cultures (13%), without 
age restriction and de-duplicated within 14-days of each index positive.18 For context we also 
analysed E. coli UTIs (EC-UTIs), defined as pure culture from urine of >104 colony-forming-
units/ml, de-duplicated within 90-days. We classified EC-BSIs/EC-UTIs as µQRVRFRPLDO¶ if 
samples were taken >48h post-admission until discharge.19 All other EC-BSIs/EC-UTIs were 
classified as µFRPPXQLW\¶, µTXDVL-FRPPXQLW\¶ or µTXDVL-QRVRFRPLDO¶ if the last hospital 
discharge was >1 year, 31-365 days, or 0-30 days previously. We also calculated incidences 
of first ever and recurrent EC-BSIs. See Supplementary Methods for further details. 
 
To account for the contribution of ageing and population growth, we standardised incidence 
for age and sex against the 1998 Oxfordshire population distribution (estimates from the UK 
Office for National Statistics). To assess ascertainment, we considered the incidence of 
blood/urine cultures, regardless of result, and also additionally standardised for culture rates. 
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As a proxy for changes in bacterial virulence, we considered 30-day mortality after, and 
levels of monocytes, neutrophils, lymphocytes, C-reactive protein (CRP), creatinine and urea 
at (closest value within [-2,+2] days) sample collection. To investigate AMR burden, which 
might also affect treatment outcomes, we assessed resistance to drugs consistently tested 
throughout the study period. Susceptibility testing was performed using disk-diffusion to 
31/Jan/2013, then by microbroth dilution (BD 3KRHQL[ Automated Microbiology System, 
Beckton Dickinson, Franklin Lakes, NJ, USA) (see Supplementary Methods). 
 
Guidelines recommend empirical treatment for uncomplicated UTIs and for urine samples to 
be sent to the laboratory only from individuals with clinical treatment failure, frequent or 
recurrent UTI or with a possibly resistant infection.16 To investigate this patient group, we 
first classified EC-BSIs according to whether the patient had ever had an EC-UTI identified 
by the laboratory ุ3 days previously. To investigate the contribution of UTI around the time 
of the EC-BSI, including where E. coli was not isolated, we classified EC-BSIs as µlikely 
urine-DVVRFLDWHG¶ (urine sample taken 3-30 days previously; EC-UTI or mixed 
growth/negative but UTI suspected clinically from request codes), µurosepsis¶ (defined as for 
likely urine-associated BSIs but urine samples within (-3,+2] days of the EC-BSI), µunlikely 
urine-associated¶ (UTI with non-E. coli pathogen or no urine sample), or µunknown¶ (other) 
(details in Supplementary Methods). To investigate the contribution of catheters, we 
classified EC-BSIs according to whether the patient had ever had a catheter urine specimen 
submitted up to and including the day of blood collection (regardless of result).  
 
To investigate the contribution of previous admission characteristics, we classified quasi-
nosocomial EC-BSIs by whether the primary diagnostic code of the antecedent admission 
was infection-related, or any diagnostic code (primary/secondary) included UTI 
(Supplementary Methods).  
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Statistical analysis 
Incidence was modelled using negative binomial regression of counts per month, binary 
outcomes using poisson regression of monthly counts (to estimate analogous rate ratios) 
and test results using median quantile regression of absolute values against sample date. 
Test results and mortality were adjusted for age and sex. Changes in trends in these 
outcomes were estimated using iterative sequential regression (Supplementary Methods),20 
and compared between outcomes using stacked regression.21 To estimate associations with 
primary care co-amoxiclav prescribing, co-amoxiclav defined-daily-doses (DDDs) per 1000 
registered patients in the previous or current year and general practice were included as 
explanatory variables (Supplementary Methods).  
 
Analyses were conducted using R 3.2.2, and STATA 14.1 for stacked regression and 
probability weighted analyses. 
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Results  
After 14-day de-duplication, from 1998-2016 5706 EC-BSIs occurred in 5215 patients (i.e. 
9% recurrences (relapse and/or reinfection)). Recurrences occurred a median(IQR) 144(39-
577) days apart: of 391 patients with recurrences, 324(83%) had one and 52(13%) had two 
(range 1-8). Overall incidence increased year-on-year (annual incidence rate ratio 
(IRR)=1·06 (95% CI 1·05-1·06)). For most EC-BSI (5393(95%)) patients were admitted to 
OUH before or within the 24h following the blood culture (remainder mostly taken in 
emergency departments or community hospitals). Only 1365(24%) EC-BSIs were 
µnosocomiaO¶ (ุ48h post-admission). A further 1132(20%) were µquasi-nosocomial¶ 
(discharged up to 30 days previously), 1346(24%) were µquasi-community¶ (discharged 31-
365 days previously) and 1863(33%) were µFRPPXQLW\¶ cases (discharged >1 year 
previously or never previously admitted to OUH).  
 
Incidence trends for EC-BSIs varied substantially with hospital-exposure (Figures 1A&2A, 
Supplementary Table 1), with overall increases clearly driven by community and quasi-
community hospital-exposure groups, and no evidence of different incidence trends between 
these two groups in 2016 (pheterogeneity=0·27). By contrast, quasi-nosocomial and nosocomial 
EC-BSIs increased more slowly. Considering only the first EC-BSI per patient or subsequent 
EC-BSIs (Figure 2A, Supplementary Figure 1) gave broadly similar results. Year-on-year 
increases in first EC-BSI became smaller (but still significant) the more recent the hospital 
exposure. Quasi-community recurrent EC-BSI were rising faster than first EC-BSIs 
(pheterogeneity<0·001) and the stable current trend in all quasi-nosocomial BSIs appeared to be 
driven by reduced recurrences in this group. 
 
After 90-day de-duplication, 228376 EC-UTIs occurred in 137075 patients (i.e. 40% 
recurrences (relapse/re-infection)). Recurrences occurred a median(IQR) 457(200-1119) 
days apart: of the 41371(30%) patients with recurrences, 22011(53%) had one and 
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8742(21%) had two (range 1-33). 12898(9%) patients had two EC-UTI within six months. 
EC-UTIs were predominantly community (160359,70%), and less commonly quasi-
community (44283,19%), quasi-nosocomial (12764,6%) or nosocomial (10970,5%) in origin. 
Rates of EC-UTI increased over 1998-2016 in community, quasi-community and quasi-
nosocomial groups, although current trends were fairly stable, but declined significantly in 
the nosocomial group (Figure 1B&2B). Furthermore, increases were accounted for entirely 
by substantial increases in recurrent UTI episodes, with decreasing overall trends in first EC-
UTI per patient (Supplementary Figure 2).  
 
In 2016, therefore, recurrences accounted for at least half of community, quasi-community 
and quasi-nosocomial EC-UTIs, and around a fifth of quasi-community and quasi-
nosocomial EC-BSIs (Supplementary Table 2). 
 
Impact of population and sampling on EC-BSI  
Blood culture submission rates increased substantially from 1998-2016 for community/quasi-
community/quasi-nosocomial groups (Figure 2A, Supplementary Figure 3), raising the 
possibility that observed increases in EC-BSIs were driven by increases in the use of blood 
cultures as a diagnostic test. However, there was no suggestion that the indications for blood 
culture changed with time: neutrophils and CRP when cultures were taken did not 
meaningfully change and there was no change in the 30-day mortality post blood culture 
sampling (Supplementary Figure 4). Further, increases in community blood culture 
submission rates were significantly smaller than increases in community EC-BSIs (p<0·001, 
Figure 2A). Standardising for age and sex explained only 10-26%, and standardising 
additionally for number of blood cultures taken 9-28%, of the increase in overall or first-per-
patient EC-BSIs, with the greatest percentage explained in nosocomial EC-BSIs and the 
least in community EC-BSIs (Supplementary Tables 3,4). In contrast, urine sample 
submission was more stable over time (Supplementary Figure 5).  
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Disease severity of EC-BSIs 
30-day mortality following EC-BSI declined slightly (IRR=0·98) in the nosocomial (p=0·03) 
and quasi-nosocomial (p=0·06) groups, but there was no evidence for changes in quasi-
community and community groups (p>0·21, adjusting for age and sex, Supplementary 
Figure 6). Mortality was substantial at 25%, 30%, 16% and 14% across the groups, 
respectively. Changes in haematology/biochemistry test results over time were small and/or 
non-significant (Supplementary Figure 6), and did not indicate that less severe infections 
were being identified, or that there were any changes in pathogen virulence.  
 
Impact of previous illness on EC-BSI 
1755(31%) EC-BSI occurred in patients with an EC-UTI  days previously (median(IQR) 
213(43-918) days previously). However, incidence trends were broadly similar for EC-BSIs 
with or without EC-UTIs ุ3 days previously, although quasi-community EC-BSIs were rising 
particularly fast in those with previous EC-UTIs (pheterogeneity<0·001, Figure 2A, 
Supplementary Figure 7). We next explored whether EC-BSI increases were associated 
with past symptomatic urinary disease, including those without positive urine cultures. 
Considering urine samples/results taken within 30 days before the EC-BSI, and 
incorporating information on mixed growth and request codes, only 760(13%) EC-BSIs were 
µlikely urine-DVVRFLDWHG¶ with 1613(28%) µurosepsis¶, 1613(28%) µXQlikely urine-associated¶ 
(of which 181[11%] had a contemporaneous urine specimen positive for another pathogen), 
and 1720(30%) unknown. However, the relative proportions of these did not vary 
substantially over time (Figure 3), suggesting no specific subgroup was associated with 
incidence increases. Percentages of EC-BSIs with a previous catheter urine specimen 
(CSU) increased with recency of hospital-exposure, being present in 365(20%) community, 
364(32%) quasi-community, 541(40%), quasi-nosocomial, 584(43%) nosocomial. However, 
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incidence trends were broadly similar for EC-BSIs with or without a previous CSU (Figure 
2A, Supplementary Figure 8), although quasi-nosocomial EC-BSIs were rising particularly 
fast in those with previous CSUs (pheterogeneity<0·001), while increases in nosocomial EC-BSIs 
were restricted to those without previous CSUs (pheterogeneity=0·03).  
 
For the 1132 quasi-nosocomial EC-BSI patients discharged in the preceding 30 days, the 
most common reasons for the antecedent admission were malignancy (395,35%), 
gastrointestinal disorders (177,16%), and renal/urological disorders (164,14%) 
(Supplementary Table 5), with no major temporal variability (Supplementary Figure 9A). 
There was no evidence that the antecedent admission was shorter than the quasi-
community group (median 2·0 (IQR:0·3-7·9) days vs 2·3 (0·3-8·2) respectively, ranksum 
p=0·15). There was strong evidence that quasi-nosocomial EC-BSIs with a UTI diagnostic 
code or an infectious primary diagnostic code for the antecendent admission were rising 
faster than those without (heterogeneity p=0·005, p<0·001 respectively, Supplementary 
Figure 9B&C), but these still comprised <25% of quasi-nosocomial EC-BSIs.  
 
Antimicrobial susceptibility 
Exploring the possibility that EC-BSI increases were associated with the development of 
AMR, the only EC-BSI antibiotic-resistant phenotype that consistently increased across all 
groups was co-amoxiclav (p<0·001; Figures 2A&4), with 212(41%) of 515 EC-BSIs in 2016 
being co-amoxclav resistant (Supplementary Table 6). Co-amoxiclav-resistant EC-BSIs 
increased significantly faster than co-amoxiclav-susceptible EC-BSIs (pheterogeneity<0·001), but 
community and quasi-community co-amoxiclav-susceptible EC-BSIs were still increasing 
significantly in 2016. Most (942/1412, 67%) co-amoxiclav-resistant EC-BSIs remained 
susceptible to gentamicin and ciprofloxacin (Figure 4).  
 
Increases in other antibiotic-resistant EC-BSIs were most notable in the community and 
quasi-community groups, with significant year-on-year increments in all but trimethoprim-
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resistant EC-BSIs, which remained stable in these groups (Supplementary Figure 10). Co-
amoxiclav-resistant EC-UTIs also rose consistently and significantly regardless of 
healthcare-exposure, but trends were more variable for other antibiotics (Supplementary 
Figure 11). In 2016, 3921/13792(28%) EC-UTIs were co-amoxiclav-resistant. 
 
Given the substantial increase in co-amoxiclav resistant EC-BSIs, we investigated whether 
there was any evidence of differential severity in susceptible and resistant cases. There was 
no strong evidence that co-amoxiclav-resistant EC-BSIs were associated with higher 
neutrophil counts in any hospital-exposure group (p>0·04, adjusting for age and sex), or that 
neutrophil counts were changing differently over time compared with co-amoxiclav-
susceptible EC-BSI (pheterogeneity>0·67; Supplementary Figure 12). Mortality was higher 
(32% (95% CI 13%-46%); p=0·002, adjusting for age and sex) for co-amoxiclav-resistant vs 
co-amoxiclav-susceptible nosocomial EC-BSIs, but not community/quasi-community/quasi-
nosocomial EC-BSIs (p>0·48), and mortality did not change differently over time in any 
group (pheterogeneity>0·35; Supplementary Figure 12, Figure 2C).  
 
Over financial years 2003-2014, the strongest associations with nosocomial co-amoxiclav-
resistant EC-BSIs were with hospital co-amoxiclav (cross-correlation 0·75) and third-
generation cephalosporin (0·80) use (Supplementary Table 7). Community prescribing data 
was only available from 2011, and co-amoxiclav-resistant EC-BSIs were too few to consider 
relationships with co-amoxiclav use. However, from 2012-2016, primary care facilities 
prescribing more co-amoxiclav in the previous year had higher rates of subsequent co-
amoxiclav-resistant-community-EC-UTIs (IRR (per 100DDD higher)=1·05 (95% CI 1·02-
1·08) p=0·003, Figure 5), and co-amoxiclav use in the previous year was a stronger 
predictor of current rates than co-amoxiclav use in the current year (p=0.003 vs p=0.64). Co-
amoxiclav use in the current year was a stronger predictor of all community-EC-UTIs 
(p=0.01 vs p=0.11) and urine specimen submission (p=0.0001 vs p=0.006), and was 
associated with higher rates of both (IRR=1·02 (1·00-1·04) p=0·01 and 1.02 (1·01-1·03) 
15 
p=0·002 respectively). Co-amoxiclav use was not associated with the proportions of E. coli-
positive specimens (p=0·68). Similar results were seen across all samples regardless of 
hospital-exposure group (Supplementary Figure 13), and also when adjusting instead for 
the proportion aged over 65 and male in 2017 per practice.   
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Discussion 
We have explored potential explanations for continuing increases in EC-BSI in Oxfordshire 
over 19 years using extensive, routinely-collected data, including diagnostic codes and 
laboratory/microbiology results. Incidence varied dramatically according to hospital-
exposure, with increases notably being driven by community/quasi-community cases. This is 
important given a new National Health Service ambition aiming to reduce Gram-negative 
BSIs by targeting healthcare-associated cases; previous successful campaigns to reduce 
methicillin-resistant Staphylococcus aureus (MRSA) BSI and Clostridium difficile infections 
also focussed on nosocomial risk factors. Our data suggest that defining appropriate 
strategies targeting community/quasi-community associated EC-BSIs might have a greater 
impact. Crucially, co-amoxiclav-resistant EC-BSIs rose significantly faster than co-
amoxiclav-susceptible EC-BSIs, regardless of hospital-exposure, with the greatest number 
of co-amoxiclav-resistant EC-BSIs in 2016 being community/quasi-community EC-BSIs. The 
association between primary care co-amoxiclav prescribing and co-amoxiclav-resistant EC-
UTIs implicates co-amoxiclav prescribing as a key driver behind these rises. Co-amoxiclav is 
one of the most commonly prescribed antibiotics nationally in both the community and 
hospitals.16,22 Our findings indicate that reduced prescribing of co-amoxiclav could reduce 
the selection pressure for EC-BSI. Despite co-amoxiclav being used for empiric BSI 
treatment, there were no clinically important changes in mortality.  
 
EC-BSI is generally considered µcommunity-acquired¶ although the true apportionment to 
community- vs healthcare-associated categories remains unclear, and there are differing 
definitions of healthcare-associated BSI.6,23 By linking to previous hospital admissions, one 
major study strength is that we could identify that incidence trends for non-nosocomial EC-
BSIs varied significantly by proximity to hospital-exposure. Blood sample submission also 
increased significantly, potentially increasing ascertainment of µPLOG¶ cases. However, blood 
cultures are key to the assessment of unwell patients whenever infection is suspected, and 
there were no clinically important changes in EC-BSI-associated severity at presentation or 
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mortality, despite substantially increasing incidence, suggesting major ascertainment bias is 
unlikely.  
 
The increasing trend in nosocomial EC-BSI was significantly smaller than for 
community/quasi-community EC-BSI in Oxfordshire, as observed nationally.8 Multiple 
infection control interventions were rolled out in UK hospitals from 2005-201024,25 in 
response to MRSA/C. difficile, and horizontal components of these initiatives could have 
contributed to these lower nosocomial rates. Consistent with this, increases in hospital-onset 
BSI caused by Gram-negative bacilli reversed after a MRSA Prevention Initiative was 
introduced in the US, while community-acquired incidence did not change.26  
 
Epidemiological differences between E. coli , MRSA and C. difficile also highlight the 
potential need for different interventions, particularly in primary care.6 In particular, 
recurrences explain relatively little of the ongoing increases in EC-BSIs, and both co-
amoxiclav-resistant and co-amoxiclav-susceptible EC-BSI are rising. Overall, 42% of EC-BSI 
appeared to be more likely amenable to urinary-focussed intervention, similar to a England-
wide study that found 51% of EC-BSIs had an underlying urogenital tract focus, with the 
largest independent risk factor for these being treatment for UTI in the prior four weeks.8 In 
our study, 13% of EC-BSIs were likely urine-associated and 28% presented as urosepsis; 
the first group may be most tractable for prevention but was smallest in both community and 
quasi-community EC-BSI, whereas urosepsis was the largest. One limitation is lack of data 
on visits to general practice; therefore, some patients may have had UTI symptoms and 
been treated empirically without a urine culture being sent, although successfully treated 
UTIs should not cause bacteraemia. Guidelines recommend urine samples be submitted 
from individuals with clinical treatment failure, frequent or recurrent UTI or with a possibly 
resistant infection;16 therefore bacteraemias due to UTI treatment failure should be 
ascertained within our data. It is hypothesised that much of the burden of EC-BSIs, and 
especially the rising incidence (in all hospital-exposure groups), arises from poor urinary 
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catheter care. However, only 20% and 30% of the community and quasi-community groups, 
where incidence is increasing fasted, had a previous CSU, and there was no evidence that 
incidence was increasing faster in those with a previous CSU versus without. One key 
limitation is that we did not have records of the presence of a catheter, but only urine 
specimens recorded as being taken from a catheter, arguing that if a catheter was present 
and causing infection, a specimen would likely have been taken from it at some time.  
 
Interestingly, there was strong evidence that quasi-nosocomial EC-BSIs with UTI or 
infectious diagnostic codes in the previous admission were rising faster than those without. 
This may reflect underlying predisposition to infection (e.g. chronic illnesses), or that prior 
antibiotic use adversely affects a SDWLHQW¶V microbiota potentially leading to 
colonisation/overgrowth by more pathogenic E. coli, thus predisposing to EC-BSI. 
 
A limitation of surveillance studies is changes in antimicrobial susceptibility testing 
methodology (here in February 2013). Whilst the proportion of isolates classified as resistant 
can vary by testing protocol,27,28 crucially changes in co-amoxiclav resistance around this 
time occurred regardless of method (Supplementary Figure 14). Recent data suggest that 
broth dilution (BD-Phoenix) and the gold standard agar dilution have high agreement;29 thus, 
rising rates of co-amoxiclav-resistant (as defined by EUCAST breakpoints) EC-BSI/EC-UTI 
are likely correct.  
 
For the first time, we have shown that GP practices with higher co-amoxiclav prescribing 
rates were more likely to have patients diagnosed with co-amoxiclav resistant EC-UTIs. 
Similar associations between trimethoprim use and trimethoprim-resistant urine-associated 
EC-BSI have been reported in adult women in England.15 Assessing usage-resistance 
associations is complicated, since changes in use of one antibiotic are generally 
accompanied by compensatory prescribing, and may be compounded by multi-drug 
resistance. Our results may therefore not be generalizable; for example, although the region 
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we studied is sizeable (~1% of the UK), we did not observe a uniform decrease in 
cephalosporin-resistant and quinolone-resistant EC-BSIs as seen in BSI caused by 
Enterobacteriaceae.14 Such differences likely reflect a complex interplay of selection 
pressures. 
 
A key limitation is that co-amoxiclav-resistant EC-BSI were too few over the period with 
contemporary prescribing data to investigate associations with antibiotic prescribing within 
the community. We were unable to assess associations between individual-patient antibiotic 
use (not available in the research database) and risk of resistant infections or between 
specific empiric regimens and outcome. However, there were no clinically important changes 
in mortality overall, by co-amoxiclav-susceptible/resistant phenotype, or by hospital-
exposure across the study period. Co-amoxiclav remains our recommended first-line empiric 
treatment for most severe infections, so the substantial increase in incidence of co-
amoxiclav-resistant bacteraemias suggests either that initial inappropriate treatment can be 
successfully rescued,30 or that the current definition of co-amoxiclav breakpoints may be 
suboptimal.31 Crucially, neither scenario supports a move towards broader empiric antibiotic 
treatment, consistent with prevailing antimicrobial stewardship messages.  
 
In summary, on-going increases in EC-BSI were driven by community and quasi-community 
cases, and cannot be attributed only to increased recurrences or an aging population. 
Absence of changes in mortality and severity do not support ascertainment bias playing a 
major role, although this cannot be excluded. Whilst urinary foci are clearly important, at 
present the scope for intervening to prevent UTIs progressing to bacteraemia could be 
limited. Notably, higher co-amoxiclav use in primary care was associated with higher rates of 
both EC-UTI and co-amoxiclav-resistant EC-UTI, supporting drives to reduce broad-
spectrum and inappropriate antibiotic use. However, despite substantial increases in co-
amoxiclav-resistant EC-BSI, evidence that patient clinical outcomes are no worse does not 
support broadening empiric antibiotic prescribing from co-amoxiclav.9  
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Figure legends 
Figure 1. Monthly (A) EC-BSI and (B) EC-UTI according to recent hospital-exposure (first 
and recurrent infections).  
Footnote: only counting EC-BSI recurrences occurring >14 days after an index positive, and 
EC-UTI recurrences occurring >90 days after an index positive. Thick blue line represents 
the estimated incidence by iterative sequential regression (ISR). Blue lines at the base of the 
graph represent 95% CI around the breakpoints estimated by the ISR model. IRR=annual 
incidence rate ratio in 2016 
 
Figure 2. Summary of incidence trends in 2016 for (A) EC-BSIs, (B) EC-UTIs, and (C) 
severity of co-amoxiclav resistant and sensitive EC-BSIs. 
Footnote: IRR=annual incidence rate ratio in 2016. See Supplementary Table 1 for numbers 
and heterogeneity tests 
 
Figure 3. Annual EC-BSI according to recent hospital-exposure and urine sample 
submission/results. 
Footnote: See Supplementary Methods for definitions. 
 
Figure 4. Annual EC-BSI susceptible and resistant to co-amoxiclav, with and without 
resistance to gentamicin and ciprofloxacin, according to recent hospital-exposure. 
Footnote: IRR=annual incidence rate ratio in 2016. 
 
Figure 5. Number of community co-amoxiclav-resistant EC-UTIs (A), community EC-UTIs 
(B) and community urine samples (C) submitted regardless of result per 1000 patients per 
GP practice 2012-2016 compared with co-amoxiclav DDD per 1000 patients per general 
practice in the previous year for the first and the current year for the last two. 
Footnote: showing one record per year per GP practice. Spearman rho (and models) for 
each panel excludes 5 which submitted less than 151 samples over 2011-2016 (all others 
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submitted over 308). Speraman rho for previous vs current for the 3 groups (U=0.20 vs 
U=0.04, U=0.33 vs U=0.35, U=0.37 vs U=0.40) 
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Supplementary Methods 
 
(a) Further details of population 
We included Escherichia coli isolated from blood from pure and mixed/polymicrobial cultures 
in our primary outcome in case differences in identification of polymicrobial infections were 
affecting incidence trends. Mixed/polymicrobial cultures comprised 763/5706 (13%) EC-BSI 
over the study. Of these, 187/763 (25%) were infections with E. coli and only plausible 
contaminants, including Coagulase negative staphylococcus; Streptococcus viridans, oralis, 
salivarius, mitis, viridans, and unspecified; diphtheroids; Propionibacterium species; and 
Bacillus species. Of the 576 EC-BSI with at least one other plausible pathogen, 412 (72%) 
other pathogens were likely gastrointestinal including Klebsiella pneumoniae and oxytoca, 
Enterococcus species, Enterococcus faecalis group D, Proteus mirabilis, Bacteroides 
fragilis, Enterobacter species, gastrointestinal anaerobes, and yeast. Percentages of 
polymicrobial infections did not vary over calendar time. 
 
We used a strict definition of nosocomial EC-BSI ending at discharge in order to investigate 
the group whose EC-BSI had not actually been identified during hospitalisation. A relatively 
small number, 44/1132 (4%), of quasi-nosocomial EC-BSI cases were discharged in the 24 
hours preceding the blood culture being taken: 147/1132 (13%) were discharged in the last 
48 hours. 
 
(b) Further details of classifications 
Urinary specimens should only be sent for microbiological testing on clinical suspicion of a 
UTI;1 however, 43% of mixed growth or culture-negative urine samples taken within [-30,+2] 
days of an E. coli bloodstream infection (EC-BSI) did not have a completed request code 
making it difficult to assess whether there really was clinicial suspicion of urinary infection 
before the bacteraemia. To investigate the contribution of antecedent UTIs to rising E. coli 
bacteraemia incidence, we therefore hierarchically classified E. coli bacteraemias as  
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(i) µlikely urine-DVVRFLDWHG¶ if they either had an E. coli-positive urine culture, or if they 
had mixed growth or negative urine culture with a relevant request code (mentioning 
UTI or other urinary symptoms, dysuria, urosepsis, pyelonephritis, positive dipstick), 
within [-30,-3] days of the EC-BSI sample 
(ii) µXURVHSVLV¶ if they either had an E. coli-positive urine culture, or if they had mixed 
growth or negative urine culture with a relevant request code within (-3,+2] days of 
the bacteraemia sample (but not (i), i.e. no pre-existing evidence of a urine infection 
which could have potentially been prevented from becoming urosepsis) 
(iii) µunlikely urine-DVVRFLDWHG¶ if they had a urine culture positive for other pathogens 
within [-30,+2] days of the EC-BSI sample, or if no urine culture was taken within [-
30,+2] days of the EC-BSI sample (but not (i) or (ii)) 
(iv) µXQNQRZQ¶ if they had a mixed growth or negative urine culture and either an 
irrelevant or no request code within [-30,+2] days of the EC-BSI sample (but not (i), 
(ii) or (iii))). 
Sensitivity analyses included definitions based on urine cultures up to 100 days before the 
EC-BSI sample rather than 30 days, with similar results (data not shown). 
 
For quasi-nosocomial bacteraemias, primary diagnostic codes from the antecedent 
admission were grouped as µFDUGLRYDVFXODUGLVRUGHU¶µQHXURORJLFDOGLVRUGHU¶
µGHUPDWRORJLFDOUKHXPDWRORJLFDOGLVRUGHUV¶µHQGRFULQHGLVRUGHU¶µREVWHWULFVDQGJ\QDHFRORJ\
disoUGHU¶µKDHPDWRORJLFDOGLVRUGHU¶µPDOLJQDQF\¶µJDVWURLQWHVWLQDOGLVRUGHU¶µRUWKRSDHGLF
GLVRUGHUVLQFOXGLQJWUDXPD¶µSRLVRQLQJ¶µUHQDODQGXURORJLFDOGLVRUGHUV¶µUHVSLUDWRU\
GLVRUGHU¶µRWKHU¶. 
 
(c) Antimicrobial susceptibility testing 
To investigate AMR burden, we assessed E. coli isolated from blood for resistance reported 
by the diagnostic laboratory to amoxicillin, co-amoxiclav, trimethoprim, gentamicin, 
ciprofloxacin, ceftriaxone, ceftazidime, piperacillin-tazobactam and meropenem, and E. coli 
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isolated from urine for resistance to amoxicillin, co-amoxiclav, trimethoprim, ciprofloxacin, 
nitrofurantoin and cefalexin (the only drugs consistently tested throughout the study period). 
Before February 2013, in the OUH microbiology service laboratory antimicrobial 
susceptibility was tested using disk diffusion in an uncontrolled inoculum using a control; in 
February 2013 this was replaced by the automated susceptibility testing with the Phoenix BD 
system using European Committee on Antimicrobial Susceptibility testing (EUCAST) 
breakpoints, using disk diffusion direct from blood in an uncontrolled inoculum as an early 
flag. In December 2013, disk diffusion in a controlled inoculum using the British Society for 
Antimicrobial Chemotherapy (BSAC) diameter zones was introduced for selected samples in 
addition to BD-Phoenix. Where multiple results were available for one sample, the Phoenix 
result was used in preference to the disk diffusion result as most disk diffusion results were 
uncontrolled; otherwise any resistant result was used in preference to susceptible results. 
Agreement between disk diffusion and Phoenix in samples where both were done was 
reasonable (Supplementary Figure 14). 
 
(d) Changes in co-amoxiclav formulation in hospital prescribing 
In July 2010, the hospital co-amoxiclav formulation changed from 250mg amoxicillin and 
125mg clavulanate to 500mg amoxicillin and 125mg clavulanate affecting defined daily 
doses (DDD) because of the different strengths. Hospital practice was to prescribe an 
additional 250mg amoxicillin with the original formulation prior to July 2010, supported by a 
concurrent decrease in raw amoxicillin DDDs in July 2010 (because it was no longer being 
prescribed with the original co-amoxiclav formulation) and increase in co-amoxiclav DDDs in 
July 2010 (as an additional 250mg amoxicillin was being counted as a co-amoxiclav DDD 
rather than an amoxicillin DDD). We therefore adjusted raw co-amoxiclav and amoxicillin 
DDDs before July 2010 to count the additional amoxicillin prescribed with the old co-
amoxiclav formulation as a co-amoxiclav DDD, making assignment consistent over the 
whole study period.  
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(e) Further details of statistical analyses 
Changes in trends in outcomes were estimated using iterative sequential regression (ISR).2 
The ISR algorithm first modelled the outcome using samples taken between 1 January 1998 
and 1 January 1999, and compared a model with one trajectory over calendar time in the 
outcome to a model allowing this trajectory to change 6 months after the start of observation. 
If the model with two trajectories was not a better fit (determined by a Bayesian Information 
Criterion being lower by at least 3.84 [the critical value to detect a significance level of 0.05 
with a Ȥ test and one degree of freedom]), an additional six PRQWK¶V observations (to June 
1999) were included. Then the model with one trajectory was compared to models with 2 
trajectories with either June 1998 or January 1999 as the changepoint, again considering 
whether any model with a change in trajectory substantially improved model fit. Any 
changepoint that improved model fit was fixed, and then an additional six PRQWK¶V data 
included. This process was iterated up to January 2017. For antibiotic resistance trends, due 
to the smaller number of observations counts per year (rather than per month) were 
modelled, first considering samples taken between 1 January 1998 and 1 January 2002, and 
then successively every year through 1 January 2017. Incidence trends in different 
subgroups or for different outcomes using stacked regression.3 
 
For standardization to the population of Oxfordshire in 1998, we used estimates from the UK 
Office for National Statistics. These were not available for 2016 so we used a linear 
extrapolation of the previous two years. 
 
Under 1% of susceptibility results were missing for each antibiotic tested, with the exception 
of trimethoprim for which blood cultures were not tested October-December 2014. Analyses 
therefore used a probability weight of 4/3 for the incidence of trimethoprim-resistant E. coli 
bacteraemias in 2014; all other analyses of incidence of resistant bacteraemias/UTIs were 
based on observed data only (i.e. complete cases). 
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Continuous test results were truncated at the 1st and 99th percentile; median values were 
modelled using quantile regression to avoid influence from outliers. All analyses of test 
results were restricted to complete cases; for EC-BSI completeness was 93% for 
neutrophils, 93% for C-reactive protein (CRP) (post-2000 only), 95% for creatinine and 93% 
for urea. CRP was reported with different upper thresholds over the study period, and 
approximately half the values were consistently above the upper threshold. CRP was 
therefore considered as a binary rather than continuous outcome, namely CRPุ156 mg/L 
(minimum upper threshold used over 1998-2016). In January 2009 the creatinine analysis 
method changed in the laboratory,2 models adjusted for this change using a step-function. 
All analyses of laboratory parameters adjusted for age and sex. 
 
In order to estimate a simple univariable association between hospital antimicrobial 
prescribing and co-amoxiclav resistant bacteremia incidence, analogous to a Spearman rho 
for two continuous factors, we calculated a bivariate cross-correlation, i.e. the correlation 
between one series at time t and another series at time t - k as a function of the time t and 
lag k. Because of differences in the time periods in which (quarterly) antibiotic prescribing 
data were available, we included only financial years 2003-2014. For each class of 
antibiotics, and all antibiotics combined, we considered a time lag of 0 (ie same quarter), and 
all quarters up to -3 and +3, (where -1/4 means antibiotic use in previous quarter against 
bacteraemias in current quarter). 
 
To estimate associations between annual community urine sample submission, community 
EC-UTI and community co-amoxiclav-resistant EC-UTI incidence, and co-amoxiclav use in 
primary care, we used backwards elimination to identify the most parsimonious model 
including co-amoxiclav defined-daily-doses (DDD) per 1000 registered patients in the current 
and previous year together with their interaction with the calendar year trend, adjusting for 
general practice. We did not consider co-amoxiclav resistant EC-BSI incidence as numbers 
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were too small over the period where antibiotic data were available. As antibiotic usage was 
only available 2011-2016, we considered annual outcomes from 2012-2016 only. Because 
incidence of co-amoxiclav resistant EC-UTIs were lower than the predicted time trend in 
2012 (Supplementary Figure 11) we allowed for this using a step function, and estimated 
time trends in addition to this. All models excluded 13 practices, 8 which had missing data 
for at least one of the years and 5 which submitted less than 151 samples over 2011-2016 
(all others submitted over 308 samples). For the outcome co-amoxiclav-resistant EC-UTI, 
the best predictor was usage in the previous year and there was no evidence of interactions 
with the calendar time trend (p=0.22). For EC-UTIs and all urines, usage in the current year 
was the better predictor and there was no evidence of interactions with the calendar time 
trend (p=0.55). The same models were chosen when including all samples regardless of 
hospital-exposure group. We also obtained 2017 demographics from the Health and Social 
Care Information Centre and included proportion aged over 65 and proportion males per GP 
practice as explanatory variables, without GP practice.  
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Supplementary Table 1 Summary of current (2016) annual rate ratios  
 
 
Insert Community 
aRR (95% CI) 
Quasi-community  
aRR (95% CI) 
Quasi-nosocomial  
aRR (95% CI) 
Nosocomial  
aRR (95% CI) 
All EC-BSI Fig. 1 1.10 (1.07-1.13) 1.08 (1.07-1.10) 1.01 (0.97-1.04) 1.03 (1.02-1.04) 
According to previous EC-BSI 
 
    
 First EC-BSI * Supp. Fig. 1 1.10 (1.07-1.13) 1.08 (1.06-1.09) 1.06 (1.05-1.08) 1.03 (1.02-1.04) 
 Recurrent EC-BSI Supp. Fig. 1 1.11 (1.05-1.18) 1.18 (1.14-1.23) 0.93 (0.85-1.01) 1.06 (1.02-1.10) 
 Heterogeneity first vs recurrence EC-BSI 
 
p=0.70 p<0.001 p=0.004 p=0.14 
All blood cultures (regardless of result) Supp. Fig. 3 1.06 (1.05-1.07) 1.08 (1.07-1.09) 1.04 (1.03-1.05) 1.03 (1.02-1.04) 
 Heterogeneity EC-BSI vs all blood cultures 
 
p<0.001 p=0.92 p=0.05 p=0.76 
According to previous EC-UTI 
 
    
 All EC-BSI with previous EC-UTI ** Supp. Fig. 6 1.13 (1.07-1.19) 1.15 (1.11-1.18) 1.02 (0.93-1.11) 1.03 (1.01-1.05) 
 All EC-BSI with no previous EC-UTI Supp. Fig. 6 1.09 (1.06-1.13) 1.06 (1.04-1.07) 0.99 (0.95-1.03) 1.02 (1.01-1.03) 
 Heterogeneity by previous EC-UTI 
 
p=0.66 p<0.001 p=0.73 p=0.02 
According to previous CSU      
All EC-BSI with previous CSU Supp. Fig. 7 1.08 (1.06-1.10) 1.09 (1.08-1.11) 1.10 (1.08-1.12) 0.93 (0.86-1.01) 
All EC-BSI with no previous CSU Supp. Fig. 7 1.09 (1.06-1.13) 1.08 (1.06-1.09) 1.06 (1.04-1.07) 1.03 (1.01-1.04) 
Heterogeneity by previous CSU  p=0.61 p=0.18 p<0.001 p=0.03 
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Insert Community 
aRR (95% CI) 
Quasi-community  
aRR (95% CI) 
Quasi-nosocomial  
aRR (95% CI) 
Nosocomial  
aRR (95% CI) 
According to co-amoxiclav susceptibility 
 
    
 Co-amoxiclav resistant EC-BSI Fig. 3 1.14 (1.11-1.17) 1.18 (1.14-1.22) 1.11 (1.05-1.17) 1.14 (1.12-1.16) 
 Co-amoxiclav susceptible EC-BSI Fig. 3 1.03 (1.02-1.04) 1.06 (1.04-1.07) 0.97 (0.93-1.00) 0.91 (0.85-0.97) 
 Heterogeneity  
 
p<0.001 p<0.001 p<0.001 p<0.001 
30-day mortality: all EC-BSI Supp. Fig 9 0.99 (0.96-1.01) 0.99 (0.96,1.01) 0.98 (0.95,1.00) 0.98 (0.96,1.00) 
CRP >156 mg/L: all EC-BSI Supp. Fig 9 0.99 (0.98,1.01) 0.99 (0.97,1.01) 1.01 (0.98,1.03) 1.00 (0.98,1.02) 
30-day mortality: co-amoxiclav sensitive EC-BSI Supp. Fig 12 0.98 (0.96,1.01) 0.99 (0.97,1.02) 0.97 (0.94,1.00) 0.96 (0.94,0.99) 
30-day mortality: co-amoxiclav resistant EC-BSI Supp. Fig 12 1.00 (0.94,1.06) 0.96 (0.91,1.02) 1.00 (0.93,1.06) 0.98 (0.95,1.02) 
All EC-UTI Fig. 1 0.99 (0.98-1.00) 1.03 (1.02-1.03) 1.00 (0.98-1.01) 0.95 (0.94-0.95) 
According to previous EC-UTI 
 
    
 First EC-UTI * Supp. Fig. 2 0.96 (0.94-0.98) 0.99 (0.98-1.00) 1.01 (1.00-1.01) 0.93 (0.93-0.94) 
 Recurrent EC-UTI Supp. Fig. 2 1.04 (1.04-1.05) 1.04 (1.03-1.05) 1.01 (0.98-1.03) 0.99 (0.97-1.00) 
 Heterogeneity  
 
p<0.001 p<0.001 p=0.99 p<0.001 
All urine cultures (regardless of result) Supp. Fig. 5 0.99 (0.98-0.99) 1.01 (1.01-1.01) 1.02 (1.01-1.02) 1.02 (1.01-1.04) 
According to co-amoxiclav susceptibility 
 
    
 Co-amoxiclav resistant EC-UTI Supp. Fig. 11 1.29 (1.18-1.40) 1.25 (1.16-1.35) 1.14 (1.10-1.19) 1.21 (1.09-1.34) 
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Insert Community 
aRR (95% CI) 
Quasi-community  
aRR (95% CI) 
Quasi-nosocomial  
aRR (95% CI) 
Nosocomial  
aRR (95% CI) 
 Co-amoxiclav susceptible EC-UTI Supp. Fig. 11 0.94 (0.92-0.97) 0.99 (0.97-1.00) 0.91 (0.87-0.95) 0.87 (0.83-0.91) 
 Heterogeneity 
 p<0.001 p<0.001 p<0.001 p<0.001 
* First ever recorded per patient between 1998-2016; all other subsequent cases counted as recurrences 
** Any EC-UTI 3 or more days prior to the EC-BSI.  
1RHYLGHQFHRIKHWHURJHQHLW\WKHUHIRUH6XSSOHPHQWDU\)LJXUHVKRZVSRROHGPRUWDOLW\WUHQGVDFURVVVXVFHSWLEOHDQGUHVLVWDnt EC-BSI 
Note: showing annual rate ratios estimated by ISR in 2016; bold p<0.001, underline p between 0.001-0.05 
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Supplementary Table 2 Relative contribution of recurrent EC-BSIs and EC-UTIs to 
total numbers in 2016 by recent hospital-exposure 
 
Community 
Recurrent/total (%) 
Quasi-community  
Recurrent/total (%) 
Quasi-nosocomial  
Recurrent/total (%) 
Nosocomial  
Recurrent/total (%) 
Bacteraemias 4/163 (2%) 24/164 (15%) 17/91 (19%) 11/98 (11%) 
UTIs 4682/9464 (49%) 2003/3097 (65%) 472/885 (53%) 148/416 (36%) 
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Supplementary Table 3 Overall EC-BSI incidence trends in 2016, unadjusted and 
standardized to the sex and age population of Oxfordshire 1998 
 
Community 
aRR (95% CI) 
(with breakpoint) 
Quasi-
community 
aRR (95% CI) 
Quasi-
nosocomial 
aRR (95% CI) 
Nosocomial 
aRR (95% CI) 
Unstandardized 1.10 (1.04-1.17) 1.08 (1.06-1.10) 1.07 (1.05-1.09) 1.03 (1.01-1.05) 
Standardized 1.09 (1.02-1.16) 1.07 (1.05-1.09) 1.06 (1.04-1.08) 1.02 (1.01-1.04) 
Percentage change in 
regression coefficient* 
10% 14% 12% 23% 
Also standardized for 
number of samples 
taken per month 
1.09 (1.02-1.16) 
 
1.07 (1.04-1.09) 
 
1.06 (1.04-1.08) 
 
1.02 (1.01-1.04) 
 
Percentage change in 
regression coefficient* 
9% 17% 12% 23% 
* difference in coefficients from standardised and unstandardized estimates expressed as a 
percentage of the unstandardized estimate. 
Note: only fitting a single trajectory to incidence for the quasi-nosocomial hospital-exposure 
group, approximating Figure 1. aRR=annual rate ratio per year in 2016; bold p<0.001, 
underline p between 0.001-0.05 
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Supplementary Table 4 First per patient EC-BSI incidence trends, unadjusted and 
standardized to the sex and age population of Oxfordshire 1998 
 
Community 
aRR (95% CI) 
(with breakpoint) 
Quasi-
community 
aRR (95% CI) 
Quasi-
nosocomial 
aRR (95% CI) 
Nosocomial 
aRR (95% CI) 
Unstandardized 1.10 (1.03-1.17) 1.07 (1.05-1.10) 1.06 (1.04-1.08) 1.03 (1.01-1.05) 
Standardized 1.09 (1.02-1.16) 1.06 (1.04-1.08) 1.05 (1.04-1.07) 1.02 (1.00-1.04) 
Percentage change in 
regression coefficient* 
10% 15% 14% 26% 
Also standardized for 
samples taken per 
month 
1.09 (1.02-1.16) 
 
1.06 (1.04-1.08) 
 
1.05 (1.04-1.07) 
 
1.02 (1.00-1.04) 
 
Percentage change in 
regression coefficient* 
9% 19% 13% 28% 
* difference in coefficients from standardised and unstandardized estimates expressed as a 
percentage of the unstandardized estimate. 
Note: aRR=annual rate ratio per year in 2016; bold p<0.001, underline p between 0.001-0.05 
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Supplementary Table 5 Primary diagnostic code for the antecedent admission for quasi-nosocomial EC-BSIs 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
Cardiovascular disorder 1 2 3 2 2 4 3 1 4 3 8 7 5 3 13 4 2 4 4 75 
Neurological disorder 1 0 2 2 1 1 2 0 0 1 2 4 2 5 3 0 2 3 3 34 
Dermatological or 
rheumatological disorders 0 1 1 0 1 1 2 0 1 2 3 1 0 3 1 2 1 2 
1 23 
Endocrine disorder 1 1 1 0 0 0 0 0 1 0 1 0 0 0 1 2 0 1 0 9 
Gastrointestinal disorder 7 7 2 3 4 2 4 6 13 4 13 10 17 7 11 12 15 17 23 177 
Gynaecological or obstetric 
disorder 1 1 1 3 1 1 4 1 2 1 1 0 1 3 0 2 4 2 
1 30 
Haematological disorder 1 0 0 1 2 0 1 0 0 0 2 2 3 2 4 2 0 1 0 21 
Malignancy 15 13 15 9 16 11 23 14 15 23 22 35 26 30 29 32 26 24 17 395 
Orthopaedic disorders 
including trauma 0 0 3 0 0 2 1 2 1 2 2 2 5 4 1 4 5 7 
3 44 
Poisoning 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3 
Renal and urological 
disorders 3 7 3 4 7 4 5 6 7 11 4 10 13 12 15 11 12 13 
17 164 
Respiratory disorder 2 1 0 3 2 4 0 1 3 4 3 7 4 5 3 4 5 7 12 70 
Dermatological disorder 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
Other 3 2 5 0 2 2 3 1 5 3 1 6 7 8 8 10 4 6 9 85 
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Supplementary Table 6 Total number and percentage of EC-BSIs and EC-UTIs tested for each antibiotic and resistant to each 
antibiotic over the whole period and in 2016 
Bacteraemias 
 
Tested(%) Resistant(%) Tested in 2016(%) Resistant in 2016(%) 
 
Amoxicillin 5689(100%) 3357(50%) 515(100%) 294(57%) 
 
Co-amoxiclav 5691(100%) 1413(20%) 515(100%) 212(41%) 
 
Trimethoprim 5362(94%) 2230(35%) 515(100%) 168(33%) 
 
Piptaz 5490(96%) 434(7%) 516(100%) 37(7%) 
 
Gentamicin 5695(100%) 327(5%) 516(100%) 40(8%) 
 
Ciprofloxacin 5694(100%) 672(10%) 516(100%) 77(15%) 
 
Ceftriaxone 5474(96%) 364(5%) 516(100%) 45(9%) 
 
Ceftazidime 5686(100%) 352(5%) 515(100%) 53(10%) 
 
Meropenem 5555(97%) 6(0%) 516(100%) 0(0%) 
 
Amikacin 1003(18%) 27(2%) 514(100%) 12(2%) 
 
Aztreonam 1703(30%) 166(9%) 515(100%) 54(10%) 
 
Cefalexin 844(15%) 211(22%) 0(0%) 0(NaN%) 
 
Cotrimoxazole 1694(30%) 484(26%) 512(99%) 140(27%) 
 
Ertapenem 2605(46%) 3(0%) 515(100%) 0(0%) 
 
Fosfomycin 918(16%) 4(0%) 512(99%) 3(1%) 
UTIs 
     
 Amoxicillin 228183(100%) 108507(39%) 13829(100%) 6329(46%) 
 Co-amoxiclav 228054(100%) 30041(11%) 13792(99%) 3921(28%) 
 Trimethoprim 228094(100%) 97281(35%) 13825(100%) 4193(30%) 
 Piptaz 59394(26%) 6098(8%) 13798(100%) 366(3%) 
 Gentamicin 59917(26%) 4305(6%) 13794(100%) 730(5%) 
 Ciprofloxacin 228128(100%) 14221(5%) 13826(100%) 1285(9%) 
 Ceftriaxone 55798(24%) 3830(6%) 13815(100%) 720(5%) 
 Ceftazidime 59615(26%) 4098(6%) 13815(100%) 683(5%) 
 Meropenem 59559(26%) 103(0%) 13793(100%) 6(0%) 
 Cefalexin 223197(98%) 45324(17%) 13780(99%) 1932(14%) 
 Cotrimoxazole 51033(22%) 13265(21%) 13746(99%) 3552(26%) 
 Ertapenem 51837(23%) 135(0%) 13787(99%) 32(0%) 
 Fosfomycin 50804(22%) 499(1%) 13777(99%) 90(1%) 
 Nitrofurantoin 226236(99%) 12032(4%) 13790(99%) 236(2%) 
 Pivmecillinam 28087(12%) 7514(22%) 13772(99%) 1346(10%) 
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Supplementary Table 7 Highest cross-correlation between hospital antimicrobial prescribing and co-amoxiclav resistant bacteremia 
incidence 
Antibiotic Highest cross-correlation and lag 
Co-amoxiclav 0.75 at lag 0 
First generation cephalosporins -0.44 at lag 3/4 
Second generation cephalosporins -0.71 at lag 0 
Third generation cephalosporins 0.80 at lag 0 
Piptaz 0.62 at lag 0 
All cephalosporins -0.59 at lag 1/4 
Imidazole -0.51 at lag 1/4 
Lincosamide 0.69 at lag 0 
Macrolide -0.31 at lag -3 
Beta lactamase resistant penicillins -0.49 at lag -2 1/4 
Beta lactamase sensitive penicillins -0.28 at lag 1 1/4 
Penicillins with extended spectrum -0.54 at lag 1/4 
Quinolone -0.45 at lag -2 1/2 
Combinations of sulfonamides and trimethoprim, including derivatives 0.35 at lag 3 1/4 
 
20 
Supplementary Figure 1. Monthly EC-BSI according to recent hospital-exposure (A) first per patient only (B) recurrences within a 
patient only 
 
Footnote: IRR=annual incidence rate ratio in 2016. See Table 1 for heterogeneity tests between first vs subsequent EC-BSIs. 
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Supplementary Figure 2. Monthly EC-UTIs according to recent hospital-exposure (A) first per patient only (B) recurrences within a 
patient only 
 
Footnote: IRR=annual incidence rate ratio in 2016. See Table1 for heterogeneity tests between first vs subsequent EC-UTIs. 
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Supplementary Figure 3. Monthly blood samples submitted for culture regardless of result according to recent hospital-exposure 
(first and repeat samples per patient) 
 
Footnote: including repeat samples submitted >14 days after an index sample. IRR=annual incidence rate ratio in 2016.  
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Supplementary Figure 4. Trends in haematology/biochemistry test results and 30-day mortality following a blood culture being taken 
regardless of its result according to recent hospital-exposure (first and recurrent infections). 
 
Footnote: including repeat samples submitted >14 days after an index sample. Fitted lines are for men (blue) and women (red) at mean age, 
IRR=annual incidence rate ratio in 2016. CM=change in median in 2016  
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Supplementary Figure 5. Monthly urine samples submitted for culture regardless of result according to recent hospital-exposure (first 
and repeat samples per patient) 
 
Footnote: including repeat samples submitted >90 days after an index sample. IRR=annual incidence rate ratio in 2016.
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Supplementary Figure 6. Trends in haematology/biochemistry test results and 30-day 
mortality following EC-BSI according to recent hospital-exposure (first and recurrent 
infections). 
 
 
Footnote: CM=change per year in median value in 2016. Adjusted for age and gender. Fitted 
lines are for men (blue) and women (red) at mean age, IRR=annual rate ratio in 2016.
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Supplementary Figure 7. Monthly EC-BSIs according to whether (A) patient had had an EC-UTI 3 days previously (B) patient had not 
had an EC-UTI 3 days previously (C) Annual EC-BSIs according to time from previous EC-UTI: 3-30 days previously, 31 to 365 days 
previously, more than 365 days previously, or never.  
 
 
Footnote: IRR=annual incidence rate ratio in 2016. See Supplementary Table 1 for heterogeneity tests between patients with and without an 
EC-UTI ุ3 days previously. Results similar restricting to EC-UTIs within the last year or 4 years. 
27 
Supplementary Figure 8. Monthly EC-BSIs according to whether (A) patient had had a catheter urine specimen (CSU) previously (B) 
patient had not had a CSU previously (C) Annual EC-BSIs according to time from previous CSU: in the previous 2 days, 3-30 days 
previously, 31 to 365 days previously, more than 365 days previously, or never. 
 
 
Footnote: IRR=annual incidence rate ratio in 2016. See Supplementary Table 1 for heterogeneity tests between patients with and without a 
CSU previously.   
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Supplementary Figure 9. Annual quasi-nosocomial EC-BSIs according to (A) for the three main categories of primary diagnostic 
codes for the antecedent admission, (B) having a UTI in any of the diagnostic codes of the previous admission to the EC-BSI, and (C) 
having the primary diagnostic code of the previous admission as an infection versus non-infection. 
 
Footnote: see Supplementary Table 5 for all diagnostic code categories.
29 
Supplementary Figure 10. Annual EC-BSIs according to recent hospital-exposure and 
antibiotic susceptibility (A) by antibiotic (B) summary 
(A) by antibiotic 
  
30 
(B) summary 
 
Footnote: IRR=annual incidence rate ratio in 2016.  
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Supplementary Figure 11. Annual EC-UTIs according to recent hospital-exposure and 
antibiotic susceptibility  
 
 
Footnote: IRR=annual incidence rate ratio in 2016.
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Supplementary Figure 12: Severity of co-amoxiclav-resistant vs susceptible EC-BSIs, by (A) neutrophil counts and (B) 30-day 
mortality across hospital exposure groups.  
 
Footnote: CM=change per year in median value in 2016. Fitted lines are for co-amoxiclav susceptible women (red and dashed), co-amoxiclav 
susceptible men (blue and dashed), co-amoxiclav resistant women (red and solid), and co-amoxiclav resistant men (blue and solid) at mean 
age. IRR=annual rate ratio in 2016. Neutrophils and mortality are both also adjusted for age and sex. No evidence of different trends between 
co-amoxiclav susceptible and co-amoxiclav resistant for either neutrophils (pheterogeneity>0.67) or 30-day mortality (pheterogeneity>0.35). 
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Supplementary Figure 13. Number of urine samples submitted regardless of result, EC-UTIs and co-amoxiclav-resistant EC-UTIs per 
1000 patients per GP practice 2012-2016 compared with co-amoxiclav DDD per 1000 patients per general practice in the previous year 
for the first and the current year for the last two (community, quasi-community, quasi-nosocomial, nosocomial groups combined) 
 
Footnote: showing one record per year per GP practice. Spearman rho (and models) for each panel excludes 5 which submitted less than 151 
samples over 2011-2016 (all others submitted over 308). Speraman rho for previous vs current for the 3 groups (U=0.2 vs U=0.05, U=0.36 vs 
U=0.38, U=0.38 vs U=0.41)
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Supplementary Figure 14: Co-amoxiclav resistance in EC-BSIs according to different 
testing methods 
 
 
Footnote: DD=disc diffusion. MIC=median inhibitory concentration by microbroth dilution 
(Phoenix) 
